IRADIMED CORP (IRMD) Fundamental Analysis & Valuation

NASDAQ:IRMD • US46266A1097

Current stock price

93.4 USD
-2.16 (-2.26%)
Last:

This IRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IRMD Profitability Analysis

1.1 Basic Checks

  • In the past year IRMD was profitable.
  • In the past year IRMD had a positive cash flow from operations.
  • Each year in the past 5 years IRMD has been profitable.
  • Each year in the past 5 years IRMD had a positive operating cash flow.
IRMD Yearly Net Income VS EBIT VS OCF VS FCFIRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M 20M 25M

1.2 Ratios

  • IRMD has a better Return On Assets (20.67%) than 98.40% of its industry peers.
  • IRMD's Return On Equity of 23.76% is amongst the best of the industry. IRMD outperforms 95.74% of its industry peers.
  • The Return On Invested Capital of IRMD (21.02%) is better than 98.40% of its industry peers.
  • IRMD had an Average Return On Invested Capital over the past 3 years of 20.45%. This is significantly above the industry average of 9.40%.
  • The last Return On Invested Capital (21.02%) for IRMD is above the 3 year average (20.45%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.67%
ROE 23.76%
ROIC 21.02%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
IRMD Yearly ROA, ROE, ROICIRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

1.3 Margins

  • IRMD has a Profit Margin of 26.82%. This is amongst the best in the industry. IRMD outperforms 96.81% of its industry peers.
  • In the last couple of years the Profit Margin of IRMD has grown nicely.
  • IRMD has a better Operating Margin (31.20%) than 98.40% of its industry peers.
  • In the last couple of years the Operating Margin of IRMD has grown nicely.
  • IRMD has a Gross Margin of 76.75%. This is amongst the best in the industry. IRMD outperforms 87.77% of its industry peers.
  • IRMD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.2%
PM (TTM) 26.82%
GM 76.75%
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
IRMD Yearly Profit, Operating, Gross MarginsIRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

9

2. IRMD Health Analysis

2.1 Basic Checks

  • IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, IRMD has more shares outstanding
  • The number of shares outstanding for IRMD has been increased compared to 5 years ago.
  • There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRMD Yearly Shares OutstandingIRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
IRMD Yearly Total Debt VS Total AssetsIRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • IRMD has an Altman-Z score of 53.76. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
  • IRMD's Altman-Z score of 53.76 is amongst the best of the industry. IRMD outperforms 98.94% of its industry peers.
  • IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 53.76
ROIC/WACC2.35
WACC8.95%
IRMD Yearly LT Debt VS Equity VS FCFIRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.3 Liquidity

  • IRMD has a Current Ratio of 7.98. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
  • IRMD's Current ratio of 7.98 is amongst the best of the industry. IRMD outperforms 88.30% of its industry peers.
  • IRMD has a Quick Ratio of 6.84. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 6.84, IRMD belongs to the best of the industry, outperforming 88.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.98
Quick Ratio 6.84
IRMD Yearly Current Assets VS Current LiabilitesIRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

8

3. IRMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.36% over the past year.
  • IRMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 36.18% yearly.
  • IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.43%.
  • The Revenue has been growing by 21.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.36% on average over the next years. This is quite good.
  • Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 10.59% on average per year.
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
EPS Next 5YN/A
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRMD Yearly Revenue VS EstimatesIRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
IRMD Yearly EPS VS EstimatesIRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

4

4. IRMD Valuation Analysis

4.1 Price/Earnings Ratio

  • IRMD is valuated quite expensively with a Price/Earnings ratio of 48.65.
  • Compared to the rest of the industry, the Price/Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 66.49% of the companies listed in the same industry.
  • IRMD is valuated expensively when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 44.02, IRMD can be considered very expensive at the moment.
  • IRMD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.15% of the companies in the same industry.
  • IRMD is valuated expensively when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 48.65
Fwd PE 44.02
IRMD Price Earnings VS Forward Price EarningsIRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 66.49% of the companies listed in the same industry.
  • IRMD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 72.23
EV/EBITDA 41.83
IRMD Per share dataIRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of IRMD may justify a higher PE ratio.
  • A more expensive valuation may be justified as IRMD's earnings are expected to grow with 12.36% in the coming years.
PEG (NY)4.63
PEG (5Y)1.34
EPS Next 2Y11.02%
EPS Next 3Y12.36%

3

5. IRMD Dividend Analysis

5.1 Amount

  • IRMD has a yearly dividend return of 0.74%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.25, IRMD pays a better dividend. On top of this IRMD pays more dividend than 90.96% of the companies listed in the same industry.
  • With a Dividend Yield of 0.74, IRMD pays less dividend than the S&P500 average, which is at 1.83.
Industry RankSector Rank
Dividend Yield 0.74%

5.2 History

  • IRMD has been paying a dividend for over 5 years, so it has already some track record.
  • The dividend of IRMD decreased recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
IRMD Yearly Dividends per shareIRMD Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • IRMD pays out 66.90% of its income as dividend. This is not a sustainable payout ratio.
DP66.9%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
IRMD Yearly Income VS Free CF VS DividendIRMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
IRMD Dividend Payout.IRMD Dividend Payout, showing the Payout Ratio.IRMD Dividend Payout.PayoutRetained Earnings

IRMD Fundamentals: All Metrics, Ratios and Statistics

IRADIMED CORP

NASDAQ:IRMD (4/10/2026, 8:00:02 PM)

93.4

-2.16 (-2.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)04-24
Inst Owners58.92%
Inst Owner Change0%
Ins Owners36.61%
Ins Owner Change-0.61%
Market Cap1.19B
Revenue(TTM)83.81M
Net Income(TTM)22.48M
Analysts82.5
Price Target121.04 (29.59%)
Short Float %6.07%
Short Ratio6.8
Dividend
Industry RankSector Rank
Dividend Yield 0.74%
Yearly Dividend1.18
Dividend Growth(5Y)N/A
DP66.9%
Div Incr Years1
Div Non Decr Years1
Ex-Date02-23
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.78%
Min EPS beat(2)1.27%
Max EPS beat(2)10.29%
EPS beat(4)4
Avg EPS beat(4)5.61%
Min EPS beat(4)0.43%
Max EPS beat(4)10.44%
EPS beat(8)7
Avg EPS beat(8)6.02%
EPS beat(12)10
Avg EPS beat(12)6.52%
EPS beat(16)14
Avg EPS beat(16)7.03%
Revenue beat(2)2
Avg Revenue beat(2)2.2%
Min Revenue beat(2)1.41%
Max Revenue beat(2)3%
Revenue beat(4)3
Avg Revenue beat(4)0.84%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)3%
Revenue beat(8)4
Avg Revenue beat(8)0.28%
Revenue beat(12)7
Avg Revenue beat(12)0.4%
Revenue beat(16)7
Avg Revenue beat(16)0.02%
PT rev (1m)-1.11%
PT rev (3m)19.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.02%
Valuation
Industry RankSector Rank
PE 48.65
Fwd PE 44.02
P/S 14.24
P/FCF 72.23
P/OCF 47.85
P/B 12.62
P/tB 13.08
EV/EBITDA 41.83
EPS(TTM)1.92
EY2.06%
EPS(NY)2.12
Fwd EY2.27%
FCF(TTM)1.29
FCFY1.38%
OCF(TTM)1.95
OCFY2.09%
SpS6.56
BVpS7.4
TBVpS7.14
PEG (NY)4.63
PEG (5Y)1.34
Graham Number17.88
Profitability
Industry RankSector Rank
ROA 20.67%
ROE 23.76%
ROCE 26.52%
ROIC 21.02%
ROICexc 43.68%
ROICexgc 47.04%
OM 31.2%
PM (TTM) 26.82%
GM 76.75%
FCFM 19.72%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
ROICexc(3y)50.3%
ROICexc(5y)54.7%
ROICexgc(3y)54.98%
ROICexgc(5y)60.13%
ROCE(3y)25.8%
ROCE(5y)22.12%
ROICexgc growth 3Y-13.69%
ROICexgc growth 5YN/A
ROICexc growth 3Y-12.49%
ROICexc growth 5YN/A
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 722.21%
Cap/Sales 10.05%
Interest Coverage 250
Cash Conversion 91.34%
Profit Quality 73.51%
Current Ratio 7.98
Quick Ratio 6.84
Altman-Z 53.76
F-Score6
WACC8.95%
ROIC/WACC2.35
Cap/Depr(3y)948.96%
Cap/Depr(5y)635.99%
Cap/Sales(3y)11.43%
Cap/Sales(5y)7.92%
Profit Quality(3y)64.21%
Profit Quality(5y)73.8%
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3Y12.36%
EPS Next 5YN/A
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.04%
EBIT growth 3Y18.71%
EBIT growth 5YN/A
EBIT Next Year15.66%
EBIT Next 3Y17.6%
EBIT Next 5YN/A
FCF growth 1Y-1.68%
FCF growth 3Y26.52%
FCF growth 5Y26.12%
OCF growth 1Y-2.64%
OCF growth 3Y35.44%
OCF growth 5Y33.79%

IRADIMED CORP / IRMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IRADIMED CORP?

ChartMill assigns a fundamental rating of 8 / 10 to IRMD.


Can you provide the valuation status for IRADIMED CORP?

ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.


What is the profitability of IRMD stock?

IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.


What is the earnings growth outlook for IRADIMED CORP?

The Earnings per Share (EPS) of IRADIMED CORP (IRMD) is expected to grow by 10.5% in the next year.


How sustainable is the dividend of IRADIMED CORP (IRMD) stock?

The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 66.9%.